| | |
 | | | Pot Stocks Get Creative in Midst of Continued Down Market | | Matthew Carr | Chief Trends Strategist | The Oxford Club | | | What the %$#! Is This $5 5G stock?
It works with Chevron, Cisco, Uber, Amazon and Wells Fargo.
It counts the U.S. Army and Department of Homeland Security as customers.
Vanguard, BlackRock, J.P. Morgan, Goldman Sachs and Citigroup have all taken HUGE positions.
And company insiders are loading up on TONS of shares.
This $5 stock could be the linchpin of the 5G revolution. The incredible story is here. |
| | | Editor's Note: A major 5G event is happening tomorrow...
President Trump recently spoke about "winning the race to be the world's leading provider of 5G."
This race could be a massive boon to a $5 stock that's doing something unprecedented.
This company has signed Verizon, AT&T, T-Mobile and Sprint to its partner list... It holds more than 200 patents... And it produces a CRUCIAL piece of 5G technology.
Investors could make a substantial sum of money. (The world's No. 1 5G investment expert just declared it "the Next Tech Giant.")
But this stock probably won't be $5 for long.
An enormous 5G spectrum auction TOMORROW could send shares skyrocketing.
Get the details on this game-changing tech now.
- Rebecca Barshop, Managing Editor
The broader markets are deep in the green for 2019.
And investors are feeling euphoric that a Santa Claus rally will push the indexes to new heights before the new year.
But there's been one bulb out in the market's string of lights... cannabis.
Pot stocks have had a 2019 to remember. Though not for the reasons we wanted.
But it doesn't mean there aren't bright spots or light bulb changes on the way. And we've recently seen once again how the sector continues to evolve.
High on the Holidays
This year, consumers are feeling relaxed.
And part of it might have to do with weed.
Thanksgiving Day, Black Friday and Cyber Monday all saw record retail sales. That's an explosive start to what's setting up to be a record holiday shopping season.
But bud is flying off the shelves as well.
Marijuana sales on "Green Wednesday" - the day before Thanksgiving that is cannabis' version of Black Friday - surged 63% over a normal Wednesday. Meanwhile, plain old Black Friday sales increased 62% over a typical Friday.
Americans increasingly popped into their local dispensaries before the family feast and frenzied shopping.
Interestingly, the biggest winners were extracts, which surged 159%. This was followed by old-school dried flower and then edibles. With big family gatherings and social holidays like Christmas and New Year's on the horizon, we can probably expect similar pops in the days before each.
In Vogue Moves
Cannabis companies are being forced to get creative.
Funding wells have gone dry as share prices wane.
And the industry is now taking a page from the biotech space.
For example, at-the-money (ATM) offerings have emerged as all the rage for cannabis companies looking to weather the current capital crunch.
This allows them to raise money by selling small increments of stock over time - at market prices - instead of issuing warrants, secondary offerings, leasebacks or underwritten deals.
Many of those increase liquidity and provide shares below market value. That's only added to pot stock volatility and the weight on share prices.
But ATM programs are more attractive because the company can start and stop as needed.
This is a tactic biotechs used a decade ago to raise billions. | | | ¿uʍop-ǝpᴉsdn
 If you or anyone you know is upside-down on a mortgage, credit card or any sort of debt...
Do one thing.
Get your hands on the new No. 1 bestselling income book on Amazon.
Claim it FREE here. | | |
| Last week, Cresco Labs (OTC: CRLBF) joined the list as the latest to hop on the ATM trend. It signed a deal with Canaccord Genuity Corp. for a $41.3 million ATM program.
So far, at least five Canadian licensed producers, as well as two American multistate operators and a real estate investment trust, have chosen the ATM path.
Though Cresco also recently announced it was abandoning its $120 million takeover of VidaCann. This is another popular trend we've covered. And I think we'll continue to see it pick up speed.
The High Five
Below are our High Five, where - each Monday - I cover the five pot stocks I believe will make major moves - up or down - in the week ahead.
1) James E. Wagner Cultivation (OTC: JWCAF) will report fourth quarter earnings tomorrow after the closing bell.
The Ontario penny pot stock entered into a vape agreement with Heritage Cannabis Holdings' CannaCure in November.
2) Medicine Man Technologies (OTC: MDCL) has been on an acquisition tear, particularly in Colorado. And one of its acquisition targets, MedPharm, announced it's launching a landmark, double-blind, placebo-controlled clinical trial in the first half of 2020. This trial to is to see how cannabis works to treat dementia and Alzheimer's.
3) IM Cannabis (CSE: IMCC) made history recently. It became the first Israeli medical cannabis company to list on the Canadian Stock Exchange. And its CEO, Oren Shuster, will be my guest on Thursday's CannaBiz Now!
The nanocap medical cannabis pioneer will hold an investor call tomorrow about its expansion in Europe and its third quarter results.
4) EnWave Corp. (OTC: NWVCF) will report fourth quarter results after the closing bell tomorrow.
Analysts are looking for a 95% increase in revenue to $10.58 million with a loss of $0.01 per share. Wall Street is also looking for first quarter guidance of a 93.7% increase in revenue to $10.29 million.
5) Veritas Farms (OTC: VFRM) will host its first-ever shareholder call on Friday afternoon.
In mid-November, Veritas reported revenue jumped 165% to $1.215 million. And revenue is up 347% year to date.
But the company has plenty to discuss as it prepares for the launch of its pet CBD products.
This week's High Five largely underperformed our benchmark, the Horizons Marijuana Life Sciences Index ETF (OTC: HMLSF), over the past month. EnWave and Medicine Man have been the leaders during that stretch. Meanwhile, IM Cannabis, James E. Wagner and Veritas have lagged.
The mood right now among pot stock investors borders on clinically depressed. Despite all the positive news, cannabis shares can't seem to find any footing to begin a new climb higher.
The Horizons Marijuana ETF continues to hover near 52-week lows. And since November 25, shares have traded below $7 as volume has petered out.
But in the U.S., we have a number of legislative successes recently. At the same time, sales in Massachusetts, Michigan and Missouri are off to blistering starts.
This week is the world's largest cannabis conference, MJBizCon in Las Vegas. My team and I will be there. And I expect what we hear there will help plot investors' courses for the year ahead.
If you have a pot stock in mind that you'd like me to discuss here, click the comment button below.
Here's to high returns,
Matthew | | | | |  | | | | | |  |  | | | | Matthew Carr | December 5, 2019 In this episode, we delve into the growing number of legislative efforts to end marijuana prohibition. Read More | | | | |  | | | | David Fessler | December 4, 2019 Increased demand from renewable energy and EVs puts the world's largest copper producers in the spotlight. Read More | | | | |  | | | | Matthew Carr | December 3, 2019 Though microcaps and nanocaps carry considerably more volatility than their larger brethren, these 10 with quadruple-digit revenue growth are worth a look. Read More | | | | | | | | | | |
|
The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. 
No comments:
Post a Comment